Phase 2 clinical trial of 18F-labeled exendin-4 for PET imaging of insulinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051200156

Enrollment

Registered

2021-03-17

Start date

2022-08-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insulinoma insulinoma

Interventions

PET scanning for insulinoma patients

E01.370.350.710.800.399

Positron-Emission Tomography

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Clinically proven presence of an insulinoma 2) Written consent has been obtained from the subject for participation in this study (16 years and older). In the case of a minor, consent has been obtained from the surrogate.

Exclusion criteria

Exclusion criteria: 1) Patients have severe liver or kidney dysfunction 2) Inability to discontinue GLP-1 related products (requires discontinuation 3 weeks before testing) 3) Patients who are unsuitable or contraindicated for exenatide administration 4) Patients with alcohol intolerance 5) Pregnant or lactating women 6) Patients who judged to be inappropriate for enrolment by the physician

Design outcomes

Primary

Measure	Time frame
detection of tumor	—

Secondary

Measure	Time frame
Safety for insulinoma patients	—

Contacts

Public ContactHiroyuki Fujimoto

Kyoto University

fujimo57@kuhp.kyoto-u.ac.jp+81-75-753-7508

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026